REFERENCES
1. Lee KJ, Wright G, Bryant H, Wiggins LA, Schuler M, Gassman NR. EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer. Cancer Drug Resist 2020;3:980-91.
2. Hong DS, Moore KN, Bendell JC, et al. Preclinical evaluation and phase Ib study of Prexasertib, a CHK1 inhibitor, and Samotolisib (LY3023414), a dual PI3K/mTOR inhibitor. Clin Cancer Res 2021;27:1864-74.
3. Witkiewicz AK, Chung S, Brough R, et al. Targeting the vulnerability of RB tumor suppressor loss in triple-negative breast cancer. Cell Rep 2018;22:1185-99.
